loader
Please Wait
Applying Filters...

Annual Sales of NCGC00024983-03 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 81Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Adalat

PharmaCompass

01

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 741

2019 Revenue in Millions : 803

Growth (%) : -8

blank

02

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 840

2020 Revenue in Millions : 741

Growth (%) : 24

blank

03

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 873

2021 Revenue in Millions : 840

Growth (%) : 4

blank

04

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 611

2022 Revenue in Millions : 873

Growth (%) : -32

blank

05

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Antihypertensives

Currency : USD

2015 Revenue in Millions : 647

2014 Revenue in Millions : 696

Growth (%) : 8%

blank

06

Brand Name : AdalatTM

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : AdalatTM

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Antihypertensives

Currency : USD

2014 Revenue in Millions : -2.50%

2013 Revenue in Millions :

Growth (%) :

blank

07

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 804

2016 Revenue in Millions : 774

Growth (%) : 4

blank

08

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2016 Revenue in Millions : 661

2015 Revenue in Millions : 671

Growth (%) : -1

blank

09

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 690

2017 Revenue in Millions : 732

Growth (%) : -6%

blank

10

Brand Name : Adalat

Nifedipine

arrow
Boulder Peptide 2024
Not Confirmed

Brand Name : Adalat

arrow
Boulder Peptide 2024
Not Confirmed

Nifedipine

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2019 Revenue in Millions : 724

2018 Revenue in Millions : 666

Growth (%) : 9

blank